TARS,STAA Stock Price and Quote

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change +0.80
Percentage change 1.97	%

Peers: XENE FOLD RDUS VKTX SRPT AXSM BTAI PRTA APLT PTCT

| Held by: VTI IWM VXF IWO IBB VTWO SCHA PJP XPH VHT

Index	RUT	P/E	-	EPS (ttm)	-2.73	Insider Own	13.75%	Shs Outstand	42.00M	Perf Week	0.27%
Market Cap	1.74B	Forward P/E	33.93	EPS next Y	1.22	Insider Trans	-1.71%	Shs Float	36.24M	Perf Month	-3.65%
Enterprise Value	1.40B	PEG	-	EPS next Q	-0.37	Inst Own	100.89%	Short Float	22.28%	Perf Quarter	-20.93%
Income	-104.94M	P/S	7.44	EPS this Y	63.52%	Inst Trans	9.98%	Short Ratio	11.89	Perf Half Y	-21.44%
Sales	233.67M	P/B	5.08	EPS next Y	208.93%	ROA	-24.69%	Short Interest	8.07M	Perf YTD	-25.23%
Book/sh	8.15	P/C	4.26	EPS next 5Y	-	ROE	-33.98%	52W High	57.28 -27.72%	Perf Year	56.76%
Cash/sh	9.71	P/FCF	-	EPS past 3/5Y	-65.92% -66.60%	ROIC	-25.32%	52W Low	20.08 106.16%	Perf 3Y	221.18%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	47.49% -	Gross Margin	92.99%	Volatility	2.29% 2.42%	Perf 5Y	-
Dividend TTM	-	EV/Sales	6.01	EPS Y/Y TTM	42.86%	Oper. Margin	-46.72%	ATR (14)	1.88	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.54	Sales Y/Y TTM	449.03%	Profit Margin	-44.91%	RSI (14)	44.37	Recom	1.29
Dividend Gr. 3/5Y	- -	Current Ratio	5.57	EPS Q/Q	36.93%	SMA20	-1.46%	Beta	0.82	Target Price	72.43
Payout	-	Debt/Eq	0.21	Sales Q/Q	183.68%	SMA50	-7.99%	Rel Volume	0.58	Prev Close	40.60
Employees	323	LT Debt/Eq	0.21	Earnings	May 01 AMC	SMA200	-8.82%	Avg Volume	679.11K	Price	41.40
IPO	Oct 16, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	12.32% 8.15%	Trades		Volume	399,143	Change	1.97%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-02-25	Resumed	Oppenheimer	Outperform	$75
May-27-25	Resumed	H.C. Wainwright	Buy	$72
Nov-20-23	Initiated	Goldman	Neutral	$19
Jul-18-23	Initiated	William Blair	Outperform	$44
May-18-23	Initiated	Guggenheim	Buy
Aug-01-22	Initiated	Barclays	Overweight	$40
Dec-21-21	Initiated	H.C. Wainwright	Buy	$40
Nov-23-21	Initiated	Oppenheimer	Outperform	$55
Nov-10-20	Initiated	Raymond James	Strong Buy	$39
Nov-10-20	Initiated	Ladenburg Thalmann	Buy	$42
Nov-10-20	Initiated	Jefferies	Buy	$35
Nov-10-20	Initiated	BofA Securities	Buy	$33

Show Previous Ratings

May-29-25 05:00PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-14-25 09:45AM	Tarsus Pharmaceuticals (TARS) Loses -15.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
May-08-25 05:00PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.05%
May-05-25 06:04PM	Tarsus Pharmaceuticals, Inc. (TARS): Among the Best Breakout Stocks to Buy According to Analysts (Insider Monkey)
May-02-25 03:17AM	Tarsus Pharmaceuticals Inc (TARS) Q1 2025 Earnings Call Highlights: Record Sales Surge and ... (GuruFocus.com) -5.84%
09:37PM	Loading…
May-01-25 09:37PM	Tarsus Pharmaceuticals, Inc. (TARS) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:35PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements (GlobeNewswire)
Apr-30-25 10:17AM	Will Declining Medical Customers Affect Cigna's Q1 Earnings? (Zacks)
09:55AM	Wall Street Analysts See a 31.89% Upside in Tarsus Pharmaceuticals (TARS): Can the Stock Really Move This High? (Zacks)
Apr-25-25 10:00AM	Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline (Zacks)
Apr-24-25 05:00PM	Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 (GlobeNewswire)
11:00AM	Universal Health to Report Q1 Earnings: Can it Surprise Wall Street? (Zacks)
Apr-23-25 01:41PM	HCA Healthcare to Report Q1 Earnings: Key Estimates to Note (Zacks)
Apr-22-25 11:19AM	Molina Healthcare to Report Q1 Earnings: Key Estimates to Watch (Zacks)
08:31AM	Loading…
08:31AM	Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting (GlobeNewswire)
Apr-21-25 04:05PM	Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders (Business Wire)
Mar-28-25 03:59PM	Baird Q4 2024 Small/Mid Cap Growth Equity Commentary (Seeking Alpha)
Mar-20-25 09:05AM	Invesco Health Care Fund Q4 2024 Commentary (SeekingAlpha)
Mar-12-25 09:49PM	Tarsus Announces Pricing of Upsized $125.0 Million Public Offering (GlobeNewswire)
04:12PM	Tarsus Announces Proposed $100.0 Million Public Offering (GlobeNewswire)
Mar-06-25 05:00PM	Tarsus to Participate in Upcoming Investor Conference (GlobeNewswire) +6.66%
Feb-26-25 02:13AM	Q4 2024 Tarsus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
02:05AM	Tarsus Pharmaceuticals Inc (TARS) Q4 2024 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com)
Feb-25-25 08:40AM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -9.33%
07:00AM	Tarsus Reports Strong Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Achievements (GlobeNewswire)
01:31AM	Tarsus Pharmaceuticals Inc (TARS) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-20-25 05:00PM	Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025 (GlobeNewswire)
Jan-30-25 05:00PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-20-25 03:31PM	Is Tarsus Pharmaceuticals (TARS) Among Billionaire Joseph Edelman's Long-Term Stock Picks? (Insider Monkey)
09:35AM	Loading…
Jan-14-25 09:35AM	Down -9.11% in 4 Weeks, Here's Why Tarsus Pharmaceuticals (TARS) Looks Ripe for a Turnaround (Zacks) -5.72%
Jan-13-25 08:30AM	Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care (GlobeNewswire) -10.76%
Dec-26-24 10:30AM	How Tarsus Pharmaceuticals' Unique Inspiration Is Driving A Triple-Digit Run (Investor's Business Daily)
Dec-04-24 09:55AM	Wall Street Analysts Think Tarsus Pharmaceuticals (TARS) Could Surge 26.98%: Read This Before Placing a Bet (Zacks)
Nov-18-24 09:55AM	Wall Street Analysts Believe Tarsus Pharmaceuticals (TARS) Could Rally 41.09%: Here's is How to Trade (Zacks)
Nov-14-24 02:15AM	Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings Call Highlights: Record Sales and Strategic ... (GuruFocus.com)
Nov-13-24 05:30PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements (GlobeNewswire)
08:30AM	Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors (GlobeNewswire)
Nov-07-24 10:00AM	Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Nov-06-24 04:30PM	Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024 (GlobeNewswire)
Nov-05-24 08:30AM	Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer (GlobeNewswire)
Oct-30-24 06:39AM	Tarsus Pharmaceuticals (TARS) Surges 10.6%: Is This an Indication of Further Gains? (Zacks)
Oct-17-24 08:30AM	Tarsus Launches Your Mitey Problem, the First Direct-to-Consumer TV Campaign for XDEMVY (lotilaner ophthalmic solution) 0.25% (GlobeNewswire)
Oct-09-24 05:56PM	Tarsus Pharmaceuticals Inc (TARS) Q2 2024 Earnings Call Highlights: Robust Sales Growth and ... (GuruFocus.com)
Sep-25-24 05:00PM	Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024 (GlobeNewswire)
Aug-28-24 05:00PM	Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference (GlobeNewswire)
Aug-08-24 09:56PM	TARS Stock Earnings: Tarsus Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace) +13.72%
06:05PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements (GlobeNewswire)
Jul-29-24 04:30PM	Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024 (GlobeNewswire)
May-29-24 05:00PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-09-24 05:00PM	Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference (GlobeNewswire) -8.86% +8.70%
12:48PM	Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q1 2024 Earnings Call Transcript (Insider Monkey)
11:06AM	Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $61 From $59, Maintains Outperform Rating (MT Newswires)
03:49AM	Tarsus Pharmaceuticals Inc (TARS) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth ... (GuruFocus.com)
May-08-24 08:58PM	TARS Stock Earnings: Tarsus Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:40PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements (GlobeNewswire)
May-06-24 09:55AM	Does Tarsus Pharmaceuticals (TARS) Have the Potential to Rally 38.7% as Wall Street Analysts Expect? (Zacks)
May-01-24 05:00PM	Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024 (GlobeNewswire) +6.59%
Apr-23-24 08:30AM	Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon (GlobeNewswire)
Apr-09-24 07:35AM	5 Best Biotech ETFs To Buy (Insider Monkey)
Apr-08-24 09:55AM	Wall Street Analysts Predict a 47.12% Upside in Tarsus Pharmaceuticals (TARS): Here's What You Should Know (Zacks)
Apr-04-24 11:33AM	Aggressive Stock Portfolio: 13 Stocks Picked by Analysts (Insider Monkey)
Apr-01-24 12:00PM	Tarsus Pharmaceuticals (TARS) Upgraded to Buy: Here's Why (Zacks)
Mar-06-24 09:55AM	How Much Upside is Left in Tarsus Pharmaceuticals, Inc. (TARS)? Wall Street Analysts Think 37.91% (Zacks)
Mar-05-24 04:30PM	Tarsus to Participate at Upcoming Investor Conferences (GlobeNewswire)
08:30AM	Tarsus Introduces Mite Party Campaign for XDEMVY (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis (GlobeNewswire)
Mar-01-24 12:07AM	Tarsus Announces Pricing of $100.0 Million Public Offering (GlobeNewswire)
Feb-29-24 04:37PM	Tarsus Announces Proposed $100.0 Million Public Offering (GlobeNewswire)
Feb-28-24 12:00PM	Here's Why Tarsus Pharmaceuticals, Inc. (TARS) is a Great Momentum Stock to Buy (Zacks)
09:58AM	Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 11:13PM	Q4 2023 Tarsus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +18.28%
06:34AM	Tarsus Pharmaceuticals Inc (TARS) Reports Robust Q4 and Full-Year 2023 Financial Results (GuruFocus.com)
06:00AM	Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements (GlobeNewswire)
Feb-22-24 08:00AM	Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept Tick-Kill Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease (GlobeNewswire)
Feb-20-24 05:00PM	Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024 (GlobeNewswire)
Jan-31-24 05:00PM	Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference (GlobeNewswire) +6.17%
Jan-30-24 04:06AM	Tarsus Pharmaceuticals, Inc. (TARS) Moves 8.5% Higher: Will This Strength Last? (Zacks)
Jan-21-24 07:01AM	11 Stocks That Will Make You Rich in 5-10 Years (Insider Monkey)
Dec-21-23 03:32PM	Tarsus Pharmaceuticals Stock Scores Relative Strength Rating Upgrade (Investor's Business Daily)
Dec-11-23 08:00AM	Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites (GlobeNewswire)
Dec-01-23 11:04PM	Insider Sell Alert: Tarsus Pharmaceuticals Inc's Dianne Whitfield Offloads 8,355 Shares (GuruFocus.com)
Nov-12-23 12:15PM	Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 04:05PM	Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements (GlobeNewswire) -5.86% +12.20%
Nov-01-23 06:35PM	Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023 (GlobeNewswire)
Sep-06-23 08:00AM	Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY, the First and Only FDA Approved Treatment for Demodex Blepharitis (GlobeNewswire)
Aug-30-23 04:30PM	Tarsus to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-28-23 10:22AM	15 Most Shorted Stocks That Are Loved By Analysts (Insider Monkey)
Aug-24-23 09:00AM	Now Available XDEMVY (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis (GlobeNewswire)
Aug-10-23 04:05PM	Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements (GlobeNewswire)
Aug-03-23 02:14PM	This Tarsus Pharmaceuticals Insider Increased Their Holding In The Last Year (Simply Wall St.)
Aug-01-23 10:30PM	Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock (GlobeNewswire) -16.99% -5.53%
Jul-31-23 04:29PM	Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock (GlobeNewswire)
Jul-25-23 07:00AM	FDA Approves XDEMVY (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis (GlobeNewswire) -24.82%
Jul-20-23 02:04PM	Why Shares of Tarsus Pharmaceuticals Are Up Thursday (Motley Fool) +15.56%
Jul-19-23 08:34PM	Tarsus Pharmaceuticals, Inc. (TARS) Surges 7.8%: Is This an Indication of Further Gains? (Zacks) +7.83%
10:13AM	Oppenheimer Says These 2 Stocks Could Double Your Money Heres Why They Could Jump (TipRanks)
Jun-12-23 08:30AM	Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis (GlobeNewswire)

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. It is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Farrow Jeffrey S	See Remarks	Jun 17 '25	Sale	40.42	13,608	550,035	36,704	Jun 18 04:07 PM
Farrow Jeffrey S	Officer	Jun 17 '25	Proposed Sale	40.42	13,608	550,088		Jun 17 04:14 PM
Lin Elizabeth Yeu	Chief Medical Officer	Jun 16 '25	Sale	41.08	1,006	41,326	7,694	Jun 17 04:07 PM
Lin Elizabeth Yeu	Officer	Jun 16 '25	Proposed Sale	41.07	1,006	41,321		Jun 16 03:07 PM
Mottiwala Aziz	Chief Commercial Officer	Jun 09 '25	Sale	43.76	17,500	765,800	47,557	Jun 11 04:50 PM
Mottiwala Aziz	Officer	Jun 09 '25	Proposed Sale	44.74	17,500	782,950		Jun 09 10:21 AM
Azamian Bobak R.	President/CEO and Board Chair	Mar 24 '25	Sale	50.00	6,000	300,000	824,106	Mar 26 04:47 PM
Azamian Bobak R.	Officer	Mar 24 '25	Proposed Sale	50.00	6,000	300,000		Mar 24 05:35 PM
Mottiwala Aziz	Chief Commercial Officer	Mar 18 '25	Sale	46.29	3,643	168,634	71,979	Mar 20 09:49 PM
Mottiwala Aziz	Chief Commercial Officer	Mar 20 '25	Sale	50.11	3,365	168,620	65,057	Mar 20 09:49 PM
Mottiwala Aziz	Chief Commercial Officer	Mar 19 '25	Sale	47.40	3,557	168,602	68,422	Mar 20 09:49 PM
Neervannan Seshadri	Chief Operating Officer	Mar 20 '25	Sale	50.11	2,435	122,018	79,682	Mar 20 09:49 PM
Neervannan Seshadri	Chief Operating Officer	Mar 18 '25	Sale	46.29	2,605	120,585	84,660	Mar 20 09:49 PM
Neervannan Seshadri	Chief Operating Officer	Mar 19 '25	Sale	47.40	2,543	120,538	82,117	Mar 20 09:49 PM
Wahl Bryan	General Counsel	Mar 18 '25	Sale	46.29	3,341	154,655	58,057	Mar 20 09:49 PM
Wahl Bryan	General Counsel	Mar 19 '25	Sale	47.40	3,261	154,571	54,796	Mar 20 09:49 PM
Wahl Bryan	General Counsel	Mar 20 '25	Sale	50.11	3,084	154,539	51,712	Mar 20 09:49 PM
Whitfield Dianne C.	Chief Human Resources Officer	Mar 18 '25	Sale	46.29	2,315	107,161	50,751	Mar 20 09:48 PM
Whitfield Dianne C.	Chief Human Resources Officer	Mar 20 '25	Sale	50.11	2,137	107,085	46,355	Mar 20 09:48 PM
Whitfield Dianne C.	Chief Human Resources Officer	Mar 19 '25	Sale	47.40	2,259	107,077	48,492	Mar 20 09:48 PM
Azamian Bobak R.	President/CEO and Board Chair	Mar 20 '25	Sale	50.11	8,534	427,639	53,635	Mar 20 09:48 PM
Azamian Bobak R.	President/CEO and Board Chair	Mar 19 '25	Sale	47.40	8,551	405,317	62,169	Mar 20 09:48 PM
Azamian Bobak R.	President/CEO and Board Chair	Mar 18 '25	Sale	46.29	7,131	330,094	70,720	Mar 20 09:48 PM
Farrow Jeffrey S	See Remarks	Mar 19 '25	Sale	47.40	1,254	59,440	23,617	Mar 20 09:48 PM
Farrow Jeffrey S	See Remarks	Mar 18 '25	Sale	46.29	1,284	59,436	24,871	Mar 20 09:48 PM
Farrow Jeffrey S	See Remarks	Mar 20 '25	Sale	50.11	1,186	59,430	22,431	Mar 20 09:48 PM
Whitfield Dianne C.	Officer	Mar 20 '25	Proposed Sale	50.11	2,137	107,093		Mar 20 04:35 PM
Farrow Jeffrey S	Officer	Mar 20 '25	Proposed Sale	50.11	1,186	59,435		Mar 20 04:30 PM
Mottiwala Aziz	Officer	Mar 20 '25	Proposed Sale	50.11	3,365	168,632		Mar 20 04:29 PM
Wahl Bryan	Officer	Mar 20 '25	Proposed Sale	50.11	3,084	154,550		Mar 20 04:21 PM
Neervannan Seshadri	Officer	Mar 20 '25	Proposed Sale	50.11	2,435	122,026		Mar 20 04:18 PM
Azamian Bobak R.	Officer	Mar 20 '25	Proposed Sale	50.11	8,534	427,669		Mar 20 04:11 PM
Neervannan Seshadri	Officer	Mar 19 '25	Proposed Sale	47.40	2,543	120,536		Mar 19 03:27 PM
Wahl Bryan	Officer	Mar 19 '25	Proposed Sale	47.40	3,261	154,569		Mar 19 03:24 PM
Azamian Bobak R.	Officer	Mar 19 '25	Proposed Sale	47.40	8,551	405,311		Mar 19 03:23 PM
Whitfield Dianne C.	Officer	Mar 19 '25	Proposed Sale	47.40	2,259	107,075		Mar 19 03:22 PM
Farrow Jeffrey S	Officer	Mar 19 '25	Proposed Sale	47.40	1,254	59,439		Mar 19 03:12 PM
Mottiwala Aziz	Officer	Mar 19 '25	Proposed Sale	47.40	3,557	168,599		Mar 19 03:12 PM
Neervannan Seshadri	Officer	Mar 18 '25	Proposed Sale	46.28	2,605	120,571		Mar 18 04:31 PM
Wahl Bryan	Officer	Mar 18 '25	Proposed Sale	46.28	3,341	154,637		Mar 18 04:26 PM
Mottiwala Aziz	Officer	Mar 18 '25	Proposed Sale	46.28	3,643	168,614		Mar 18 04:26 PM
Whitfield Dianne C.	Officer	Mar 18 '25	Proposed Sale	46.28	2,315	107,149		Mar 18 04:20 PM
Azamian Bobak R.	Officer	Mar 18 '25	Proposed Sale	46.28	7,131	330,055		Mar 18 04:15 PM
Farrow Jeffrey S	Officer	Mar 18 '25	Proposed Sale	46.28	1,284	59,429		Mar 18 04:12 PM
Goldberg Andrew D.	Director	Mar 07 '25	Option Exercise	12.89	7,000	90,230	13,350	Mar 11 04:01 PM
LINK WILLIAM J PHD	Director	Aug 12 '24	Sale	26.08	35,000	912,961	0	Aug 14 04:34 PM
FLYING L PARTNERS XI LLC	Director	Aug 12 '24	Proposed Sale	26.85	35,000	939,750		Aug 12 04:25 PM

Dollar change +0.50
Percentage change 3.00	%

STAA Staar Surgical Co daily Stock Chart

Peers: JNJ ALGN ISRG MDT ABT NVS BSX EW EYE SYK

| Held by: IJR VTI VB IWM VXF VBK IWO SPSM VTWO IJT

Index	RUT	P/E	-	EPS (ttm)	-1.44	Insider Own	0.54%	Shs Outstand	49.52M	Perf Week	1.12%
Market Cap	850.86M	Forward P/E	104.14	EPS next Y	0.16	Insider Trans	-	Shs Float	49.26M	Perf Month	-8.47%
Enterprise Value	664.78M	PEG	-	EPS next Q	-0.56	Inst Own	107.95%	Short Float	11.35%	Perf Quarter	-3.32%
Income	-71.08M	P/S	3.05	EPS this Y	-552.09%	Inst Trans	14.24%	Short Ratio	6.25	Perf Half Y	-29.18%
Sales	279.13M	P/B	2.43	EPS next Y	116.99%	ROA	-14.97%	Short Interest	5.59M	Perf YTD	-29.27%
Book/sh	7.07	P/C	3.82	EPS next 5Y	19.86%	ROE	-19.14%	52W High	49.86 -65.54%	Perf Year	-57.17%
Cash/sh	4.50	P/FCF	-	EPS past 3/5Y	- -	ROIC	-18.55%	52W Low	13.50 27.26%	Perf 3Y	-72.33%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	10.85% 15.89%	Gross Margin	73.48%	Volatility	2.68% 3.31%	Perf 5Y	-62.55%
Dividend TTM	-	EV/Sales	2.38	EPS Y/Y TTM	-557.38%	Oper. Margin	-24.26%	ATR (14)	0.85	Perf 10Y	65.03%
Dividend Ex-Date	-	Quick Ratio	4.07	Sales Y/Y TTM	-14.44%	Profit Margin	-25.46%	RSI (14)	47.57	Recom	2.83
Dividend Gr. 3/5Y	- -	Current Ratio	4.78	EPS Q/Q	-1508.49%	SMA20	-0.95%	Beta	0.60	Target Price	18.67
Payout	-	Debt/Eq	0.10	Sales Q/Q	-44.94%	SMA50	-3.97%	Rel Volume	1.28	Prev Close	16.68
Employees	1211	LT Debt/Eq	0.09	Earnings	May 07 AMC	SMA200	-25.80%	Avg Volume	895.18K	Price	17.18
IPO	Jul 07, 1983	Option/Short	Yes / Yes	EPS/Sales Surpr.	14.14% 5.57%	Trades		Volume	1,153,843	Change	3.00%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-21-25	Initiated	Wells Fargo	Equal Weight	$17
Feb-12-25	Downgrade	William Blair	Outperform → Mkt Perform
Feb-12-25	Downgrade	Mizuho	Outperform → Neutral	$45 → $17
Feb-12-25	Downgrade	Jefferies	Buy → Hold
Feb-12-25	Downgrade	BTIG Research	Buy → Neutral
Jul-15-24	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$50 → $37
Jun-11-24	Upgrade	BTIG Research	Neutral → Buy	$46
Mar-11-24	Upgrade	Stifel	Hold → Buy	$30 → $50
Dec-05-23	Downgrade	Needham	Buy → Hold
Dec-04-23	Initiated	Morgan Stanley	Equal-Weight	$35
Sep-15-23	Downgrade	The Benchmark Company	Buy → Hold
Aug-03-23	Downgrade	Canaccord Genuity	Buy → Hold	$77 → $48
Jun-07-23	Downgrade	William Blair	Outperform → Mkt Perform
Apr-17-23	Initiated	Piper Sandler	Neutral	$65
Feb-06-23	Downgrade	BTIG Research	Buy → Neutral
Dec-28-22	Reiterated	BTIG Research	Buy	$80 → $67
Dec-08-22	Initiated	Stifel	Hold	$60
Nov-07-22	Upgrade	Sidoti	Neutral → Buy
Oct-14-22	Resumed	Stephens	Overweight	$91
Oct-13-22	Initiated	Mizuho	Buy	$85

Show Previous Ratings

Jun-17-25 11:31PM	Q1 Earnings Roundup: STAAR Surgical (NASDAQ:STAA) And The Rest Of The Medical Devices & Supplies - Specialty Segment (StockStory)
Jun-11-25 06:24AM	STAA Q1 Earnings Call: Tariff Mitigation, Cost Cuts, and China Inventory Reshape Outlook (StockStory)
May-22-25 07:00AM	STAAR Surgical Announces Participation in Upcoming Investor Conferences (Business Wire)
May-16-25 12:50PM	STAAR Surgical plans $30m share buyback despite China market woes (Medical Device Network) +5.08%
07:00AM	STAAR Surgical Announces $30 Million Share Repurchase Authorization (Business Wire)
03:39AM	Loading…
May-08-25 03:39AM	Staar Surgical Co (STAA) Q1 2025 Earnings Call Highlights: Navigating Challenges and Optimizing ... (GuruFocus.com)
May-07-25 11:51PM	STAAR Surgical projects significant China revenue rebound in Q3 2025 amid tariff mitigation and new product launch (Seeking Alpha)
11:51PM	STAAR Surgical Company (STAA) Q1 2025 Earnings Call Transcript (Seeking Alpha)
07:00PM	Staar Surgical (STAA) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:45PM	Staar Surgical (STAA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:41PM	Staar Surgical: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	STAAR Surgical Reports First Quarter 2025 Results (Business Wire)
Apr-29-25 09:06AM	3 Dawdling Stocks That Concern Us (StockStory)
Apr-24-25 05:00PM	STAAR Surgical Announces Changes to Board of Directors (Business Wire)
Apr-23-25 07:00AM	STAAR Surgical to Host First Quarter 2025 Earnings Conference Call and Webcast on May 7, 2025 (Business Wire)
03:07PM	Loading…
Apr-11-25 03:07PM	Couchbase, Staar Surgical, Zymeworks, and More Stocks See Action From Activist Investors (Barrons.com) +7.84%
05:15AM	Spotting Winners: STAAR Surgical (NASDAQ:STAA) And Medical Devices & Supplies - Specialty Stocks In Q4 (StockStory)
Apr-08-25 09:34PM	STAAR Surgical Company (STAA): Among Stocks Insiders Bought in April After Trump's Tariff Rollout (Insider Monkey) -6.51% +5.17%
05:04AM	Medical Devices & Supplies - Specialty Stocks Q3 Recap: Benchmarking STAAR Surgical (NASDAQ:STAA) (StockStory)
Mar-17-25 06:30PM	STAAR Surgical Announces Realignment of Leadership Structure (Business Wire)
Mar-07-25 08:01AM	3 Stocks Under $50 in Hot Water (StockStory)
Mar-04-25 11:00AM	Staar Surgical names Stephen Farrell as CEO (MedTech Dive) +7.77%
Feb-28-25 04:03AM	A Look Back at Medical Devices & Supplies - Specialty Stocks Q3 Earnings: STAAR Surgical (NASDAQ:STAA) Vs The Rest Of The Pack (StockStory)
Feb-26-25 04:45PM	STAAR Surgical Announces Leadership Transition (Business Wire)
06:02AM	Staar Surgical to lay off 115 people in California (MedTech Dive)
Feb-19-25 04:51AM	What To Expect From Staar Surgical Co (STAA) Q4 2024 Earnings (GuruFocus.com) +6.86%
Feb-12-25 09:44AM	Tesla, Instacart initiated: Wall Street's top analyst calls (The Fly) -24.68%
05:14AM	Staar Surgical: Q4 Earnings Snapshot (Associated Press Finance)
02:13AM	Staar Surgical Co (STAA) Q4 2024 Earnings Call Highlights: Navigating Challenges and Opportunities (GuruFocus.com)
Feb-11-25 04:01PM	STAAR Surgical Reports Fourth Quarter and Fiscal Year 2024 Results (Business Wire)
07:00AM	Loading…
Jan-13-25 07:00AM	STAAR Surgical to Host Fourth Quarter and Fiscal Year 2024 Earnings Conference Call and Webcast on February 19, 2025 (Business Wire)
Jan-04-25 07:50AM	Staar Surgical price target lowered to $39 from $49 at BTIG (TipRanks)
Nov-25-24 07:00AM	STAAR Surgical to Participate in BTIG Ophthalmology Day (Business Wire) +7.01%
Nov-13-24 10:05AM	Implied Volatility Surging for STAAR Surgical (STAA) Stock Options (Zacks)
07:00AM	STAAR Surgical to Participate in Stephens Annual Investment Conference (NASH2024) (Business Wire)
Nov-04-24 09:15AM	A Dive into Staar Surgical (STAA) International Revenue Trends and Forecasts (Zacks)
05:15AM	STAAR Surgical and Lucy Bronze, MBE, See Eye to Eye on Vision Correction (PR Newswire)
Nov-02-24 09:00AM	Staar Surgical Co (STAA) Q3 2024 Earnings Call Highlights: Strong Sales Growth Amidst Challenges (GuruFocus.com)
Oct-30-24 10:21PM	CORRECTING and REPLACING STAAR Surgical Reports Third Quarter 2024 Results (Business Wire)
05:35PM	Staar Surgical (STAA) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
04:33PM	Staar Surgical: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	STAAR Surgical Reports Third Quarter 2024 Results (Business Wire)
Oct-29-24 09:11AM	What To Expect From Staar Surgical Co (STAA) Q3 2024 Earnings (GuruFocus.com)
Oct-23-24 07:00AM	STAAR Surgical to Report Third Quarter Results on October 30, 2024 (Business Wire)
Oct-07-24 09:55AM	Here's Why Staar Surgical (STAA) Could be Great Choice for a Bottom Fisher (Zacks)
Sep-27-24 09:55AM	Wall Street Analysts Predict a 43.93% Upside in Staar Surgical (STAA): Here's What You Should Know (Zacks) +9.92%
Sep-23-24 07:00AM	STAAR Surgical Experience Center Expands to Meet Growing Surgeon Demand (Business Wire)
Sep-17-24 08:00AM	Sidoti Events, LLC's Virtual September Small-Cap Conference (ACCESSWIRE)
Sep-16-24 12:00PM	Staar Surgical (STAA) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Sep-06-24 01:01PM	Baillie Gifford Reduces Stake in Staar Surgical Co (GuruFocus.com)
Aug-13-24 10:48AM	Implied Volatility Surging for STAAR Surgical (STAA) Stock Options (Zacks)
Aug-12-24 09:15AM	Why Staar Surgical (STAA) International Revenue Trends Deserve Your Attention (Zacks)
Aug-07-24 11:53PM	STAA Stock Earnings: Staar Surgical Misses EPS, Beats Revenue for Q2 2024 (InvestorPlace) +11.03%
08:00PM	Staar Surgical (STAA) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
05:20PM	Staar Surgical (STAA) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
04:22PM	Staar Surgical: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	STAAR Surgical Reports Second Quarter 2024 Results (Business Wire)
Jul-31-24 07:00AM	STAAR Surgical to Report Second Quarter Results on August 7, 2024 (Business Wire)
Jul-30-24 07:00AM	STAAR Surgical to Participate in Canaccord Genuity 44th Annual Growth Conference (Business Wire)
Jun-27-24 01:25PM	Staar Surgical Stock Earns RS Rating Upgrade (Investor's Business Daily)
04:01AM	Staar Surgical (STAA) Soars 7.5%: Is Further Upside Left in the Stock? (Zacks)
Jun-05-24 07:00AM	STAAR Surgical to Participate in Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
May-13-24 11:06AM	Don't Overlook Staar Surgical (STAA) International Revenue Trends While Assessing the Stock (Zacks)
May-08-24 11:06AM	STAAR Surgical Company (NASDAQ:STAA) Q1 2024 Earnings Call Transcript (Insider Monkey) -12.07%
10:17AM	Mizuho Adjusts STAAR Surgical's Price Target to $55 From $53, Keeps Buy Rating (MT Newswires)
07:59AM	Morgan Stanley Raises Price Target on STAAR Surgical to $50 From $35, Keeps Equalweight Rating (MT Newswires)
03:43AM	Staar Surgical Co (STAA) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth Amid ... (GuruFocus.com)
May-07-24 11:54PM	STAA Stock Earnings: Staar Surgical Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:30PM	Staar Surgical (STAA) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
05:58PM	Staar Surgical Co Reports Q1 2024 Results: Misses Earnings Projections Despite Revenue Growth (GuruFocus.com)
05:26PM	Staar Surgical: Q1 Earnings Snapshot (Associated Press Finance)
04:03PM	STAAR Surgical Reports First Quarter 2024 Results (Business Wire)
04:01PM	STAAR Surgical Announces Milestone Strategic Agreement in U.S. with IQ Laser Vision (Business Wire)
May-06-24 09:16AM	Wall Street's Insights Into Key Metrics Ahead of Staar Surgical (STAA) Q1 Earnings (Zacks)
May-01-24 07:00AM	STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel (Business Wire)
Apr-29-24 07:00AM	STAAR Surgical to Report First Quarter Results on May 7, 2024 (Business Wire)
Apr-25-24 03:43PM	Staar Surgical Stock Climbs The Leadership Ladder With Jump To 84 RS Rating (Investor's Business Daily)
Apr-05-24 09:15AM	Strength Seen in Staar Surgical (STAA): Can Its 16.5% Jump Turn into More Strength? (Zacks) +6.97%
Apr-04-24 04:26PM	Staar Surgical, A Lasik Rival, Just Crushed Quarterly Views; But Is Its 2026 Target Too Aggressive? (Investor's Business Daily) +16.48%
03:54PM	Eye Lens Maker STAAR Surgical Expects Q1 Sales To Beat Consensus (Benzinga)
07:00AM	STAAR Surgical Announces Preliminary Net Sales for First Quarter 2024 (Business Wire)
Apr-02-24 07:00AM	STAAR Surgical Celebrates Three Million Lens Milestone at ASCRS Meeting, Unveils New EVO ICL Data and Latest Innovation for 2024 (Business Wire)
Mar-26-24 11:45AM	Nvidias Market Cap Myopia: 3 Stocks Proving Size Isnt Everything (InvestorPlace)
Mar-20-24 04:22AM	STAAR Surgical Celebrates Three Million Implantable Collamer® Lenses (PR Newswire)
Mar-18-24 07:00AM	STAAR Surgical Celebrates Three Million Implantable Collamer Lenses (Business Wire)
Mar-12-24 10:30AM	Sidoti Events, LLC's Virtual March Small-Cap Conference (ACCESSWIRE)
07:00AM	STAAR Surgical Adds Arthur Butcher and Wei Jiang to Board of Directors (Business Wire)
Mar-06-24 07:00AM	STAAR Surgical to Participate in Two Upcoming Investor Conferences (Business Wire) +6.67%
Feb-28-24 10:58AM	STAAR Surgical Company (NASDAQ:STAA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 02:00PM	Staar Surgical (STAA) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
Feb-26-24 05:30PM	Staar Surgical (STAA) Beats Q4 Earnings Estimates (Zacks)
04:39PM	Staar Surgical: Q4 Earnings Snapshot (Associated Press Finance)
04:34PM	Staar Surgical Co (STAA) Posts Solid Growth in Q4 and FY 2023, Affirms Positive Outlook for 2024 (GuruFocus.com)
04:01PM	STAAR Surgical Reports Fourth Quarter and Fiscal Year 2023 Results (Business Wire)
Feb-19-24 07:00AM	STAAR Surgical to Report Fourth Quarter Results on February 26, 2024 (Business Wire)
Jan-27-24 01:03PM	Baillie Gifford Adjusts Position in Staar Surgical Co (GuruFocus.com)
Jan-23-24 07:00AM	STAAR Surgical Announces Strategic Agreement in U.S. with SharpeVision (Business Wire)
Jan-12-24 06:49PM	Howard Hughes, Carrier, and More Stocks See Action From Activist Investors (Barrons.com) -5.14%
Jan-08-24 07:00AM	STAAR Surgical Announces Preliminary Results for Fourth Quarter and Fiscal 2023 (Business Wire) +11.52%
Dec-17-23 12:35PM	7 Stocks with Strong Insider Buying: December 2023 (InvestorPlace)

STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The firm offers implantable lenses for the eye and accessory delivery systems. Its products include refractive and cataract solutions through the Collamer brand. The company was founded in 1982 and is headquartered in Lake Forest, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BROADWOOD PARTNERS, L.P.	10% Owner	Apr 08 '25	Buy	15.32	178,127	2,729,095	13,510,391	Apr 10 07:00 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Apr 09 '25	Buy	15.08	8,200	123,676	13,518,591	Apr 10 07:00 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Apr 10 '25	Buy	15.18	900	13,658	13,519,491	Apr 10 07:00 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Apr 04 '25	Buy	15.91	497,631	7,917,191	13,194,210	Apr 07 08:28 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Apr 03 '25	Buy	16.97	209,535	3,555,138	12,696,579	Apr 07 08:28 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Apr 07 '25	Buy	15.61	138,054	2,155,174	13,332,264	Apr 07 08:28 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Apr 02 '25	Buy	17.43	31,780	553,925	12,487,044	Apr 02 08:33 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Mar 31 '25	Buy	17.46	22,189	387,360	12,455,264	Apr 02 08:33 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Mar 26 '25	Buy	17.50	101,633	1,778,517	12,421,324	Mar 28 06:45 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Mar 28 '25	Buy	17.47	8,131	142,014	12,433,075	Mar 28 06:45 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Mar 27 '25	Buy	17.48	3,620	63,294	12,424,944	Mar 28 06:45 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Mar 21 '25	Buy	17.74	102,400	1,816,545	12,285,395	Mar 25 07:02 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Mar 25 '25	Buy	17.44	34,296	598,177	12,319,691	Mar 25 07:02 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Mar 20 '25	Buy	17.96	108,720	1,952,992	12,182,995	Mar 20 07:51 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Mar 18 '25	Buy	17.54	93,124	1,633,291	12,074,275	Mar 20 07:51 PM
Foust Warren	Chief Operating Officer	Mar 12 '25	Option Exercise	0.00	8,175	0	26,088	Mar 14 07:24 PM
Michna Magda	Chief Clinical, Regulatory,	Mar 12 '25	Option Exercise	0.00	6,177	0	18,554	Mar 14 07:21 PM
SISITSKY NATHANIEL	General Counsel	Mar 12 '25	Option Exercise	0.00	5,827	0	27,762	Mar 14 07:20 PM
Williams Patrick F.	Chief Financial Officer	Mar 12 '25	Option Exercise	0.00	8,153	0	56,242	Mar 14 07:19 PM
Williams Patrick F.	Chief Financial Officer	Mar 10 '25	Option Exercise	0.00	4,061	0	48,089	Mar 11 08:40 PM
Williams Patrick F.	Chief Financial Officer	Mar 07 '25	Option Exercise	0.00	5,689	0	44,028	Mar 11 08:40 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Mar 04 '25	Buy	17.24	27,953	481,849	11,981,151	Mar 06 07:07 PM
FARRELL STEPHEN C	President & CEO	Mar 05 '25	Option Exercise	6.95	20,000	138,900	35,156	Mar 06 05:47 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Feb 27 '25	Buy	17.05	259,316	4,420,106	11,548,753	Mar 03 07:12 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Mar 03 '25	Buy	16.64	249,503	4,151,214	11,953,198	Mar 03 07:12 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Feb 28 '25	Buy	17.45	154,942	2,704,235	11,703,695	Mar 03 07:12 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Feb 12 '25	Buy	14.96	259,616	3,883,255	11,137,623	Feb 14 07:00 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Feb 13 '25	Buy	15.84	115,282	1,825,514	11,252,905	Feb 14 07:00 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Feb 14 '25	Buy	15.49	36,532	565,998	11,289,437	Feb 14 07:00 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Jan 14 '25	Buy	21.46	21,155	454,086	10,869,786	Jan 16 07:20 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Jan 16 '25	Buy	21.50	8,221	176,753	10,878,007	Jan 16 07:20 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Dec 16 '24	Buy	24.24	53,500	1,297,084	10,821,931	Dec 18 07:00 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Dec 18 '24	Buy	24.33	23,000	559,493	10,848,631	Dec 18 07:00 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Dec 17 '24	Buy	24.58	3,700	90,963	10,825,631	Dec 18 07:00 PM
Butcher Arthur C	Director	Aug 12 '24	Buy	37.99	1,315	49,957	4,208	Aug 19 05:31 PM

TARS

Tarsus Pharmaceuticals Inc

STAA

Staar Surgical Co

Upgrade your FINVIZ experience